Background {#Sec1}
==========

Leprosy is a chronic infectious disease caused by *Mycobacterium leprae*. The bacilli invades Schwann cells and macrophages of the skin leading the tissue injury, which is the major reason for its pathogenesis \[[@CR1]--[@CR3]\]. Leprosy presents a wide variety of clinical presentations, including the indeterminate (I), tuberculoid (TT), borderline (BT, BB, BL) and lepromatous (LL) forms. In addition, about 20--50% of leprosy patients, depending on the population studied, can be affected by acute inflammatory episodes known as leprosy reactions, as so called type 1 (Reversal Reaction) or type 2 (Erythema Nodosum Leprosum- ENL) \[[@CR4], [@CR5]\]. Either RR or ENL are observed in all borderline forms prior, during or after completion of multidrug therapy. RR involves the active participation of T lymphocytes and abrupt episodes of intense local delayed-type hypersensitivity to *M. leprae* in skin and/or nerves. On the other hand, ENL is typical of the BL and LL forms and is correlated to a systemic reaction involving a cytokine storm and also deposition of immune complexes in skin and organs \[[@CR6], [@CR7]\]. Regardless its type, leprosy reactions are an important contributing factor of nerve damage among patients with leprosy. The identification of host-derived biomarkers correlated to leprosy reactions might point out new tests to predict increased risk of developing the occurrence of reactional episodes thus helping to prevent its irreversible sequels. There are only a few transcriptomic studies searching for genes related to the development of leprosy reactions. Among these, a role for pro and anti-inflammatory regulators, IFN-induced genes, complement components, among others have been described \[[@CR5], [@CR6], [@CR8]\].

Methods {#Sec2}
=======

In this study we analyzed the expression of a panel of relevant immune response genes in RNA-derived from peripheral blood leukocytes of leprosy patients with and without reactions in order to identify gene expression signatures associated with either RR or ENL. One hundred and fifty one cDNA samples of patients divided into three groups were used: 57 patients with no evidence of reactions (hereinafter referred to as No Reaction Group - NR), 50 patients with RR and 44 patients with ENL. Subjects were diagnosed according to the Brazilian's Ministry of Health guidelines in the leprosy outpatient clinics from Hospital Universitário Professor Edgard Santos and Hospital Couto Maia in the city of Salvador-Bahia, Brazil. Patients were classified according to a Ridley--Jopling classification and by the WHO field classification \[[@CR9], [@CR10]\], as previously reported for studies of patients recruited from this hospital in Salvador \[[@CR11]\]. Detailed complementary data about the participants are described in Table [1](#Tab1){ref-type="table"}. Written informed consent was obtained from all patients after approval of the study by the Ethics Committee from the Federal University of Bahia (number 891.963). Peripheral leukocytes from patients free of immunosuppressants such as thalidomide or prednisone were homogenized in TRIzol (Thermo Fisher Scientific). RNA was extracted using the PureLink ™ RNA Mini Kit (Thermo Fisher Scientific) and the total RNA concentration was determined in optical density spectrophotometer (260 and 280 nm). The cDNA conversion was performed using the High Capacity cDNA Reversion Transcription Kit (Applied Biosystems) following the manufacturer's instructions. The expression of 90 target genes and 4 normalizing genes was performed by medium- throughput quantitative q-PCR using the microfluidic system Biomark (Fluidigm, CA). The analysis was performed from the real-time fluorescence accumulation data of each sample (ΔRn), using the logistic function adjustment of four parameters to represent each amplification curve by the library of qpcR (R Development Core Team, 2009) version 2.922. Results: After filtering by QC, 35 genes were excluded and 55 analyzed. We first compared the paucibacillary (PB) versus multibacillary (MB) leprosy within the unreactional (NR) group checking for differences regarding these two disease poles. This analysis did not show any significant differences (*p* \< 0.05, data not shown). Nevertheless, there was a differential pattern of gene expression between the NR and RR group as shown in Table [2](#Tab2){ref-type="table"}. A set of genes belonging to different pathways that includes the *parkin* pathway, pattern recognition receptors (PRRs), type I IFNs precursors, inflammatory cytokines and chemokines and eicosanoid metabolism were significantly more expressed in RR patients as compared to the NR group (Fig. [1](#Fig1){ref-type="fig"}). This peculiar inflammatory signature for type 1 reaction has been described in previous works \[[@CR5], [@CR8]\] that also underpinned a mixed immune activation that seems to lead to the RR pathogenesis. On the other hand, only *PARK2* was significantly more expressed in leucocytes of ENL compared to unreactional patients (logFC =2.13 e *p* = 0.04), as well as TLR7 between RR and ENL subjects (logFC = − 2.72 e *p* = 0.02).Table 1Demographic and clinical characteristics of leprosy patientsA - Characteristics of the sample^a^N individualsAge, years\
± SDGender M:FCases / Reaction9444.05 (13.31)58:36Controls / No Reaction5745.21 (14.98)28:29B - Clinical characteristics of the cohort^a^*Clinical phenotypen(%)* Tuberculoid (TT)20(13) Borderline tuberculoid (BT)30(20) Borderline (BB)18(12) Borderline lepromatous (BL)17(11) Lepromatous (LL)49(32) Indeterminate leprosy (I)11(7) Other forms (Neural)6(4)*Total\#151(100)*C - Patients with reaction episode^a^ RR50(53) ENL44(47)*Total\#94(62)*D - Patients without reaction episode^a^ PB47(82) MB10(18)*Total\#57(38)*^a^Results are shown as N(%). Abbreviations: *SD* Standart deviation, *M* male, *F* female, *PB* paucibacillary, *MB* multibacillary, *RR* reversal reaction, *ENL* erythema nodosum leprosum. Patients were also classified under leprosy clinical spectrum according to Ridley & Jopling \[[@CR9]\]Table 2Normalized gene expression values of whole blood leukocytes samples of leprosy patients with reactions (*n* = 94) and leprosy patients without reactions (*n* = 57)Reaction vs No ReactionGeneDescriptionlog fold change*p*.value\*CCL2C-C Motif Chemokine Ligand 24.040.0016PARKparkinson protein 2, E3 ubiquitin protein ligase3.270.0036ALOX5Arachidonate 5-Lipoxygenase2.990.0108TLR7Toll Like Receptor 72.980.011LRRK2Leucine Rich Repeat Kinase 23.090.0161IFNBinterferon beta 12.360.0228TLR10Toll Like Receptor 103.070.0236IL18Interleukin 182.340.0326TLR3Toll Like Receptor 32.740.0338CLEC5AC-Type Lectin Domain Containing 5A2.810.0446RR vs No Reaction CCL2C-C Motif Chemokine Ligand 24.310.0002 TLR7Toll Like Receptor 73.810.0012 PARKparkinson protein 2, E3 ubiquitin protein ligase3.160.002 ALOX5Arachidonate 5-Lipoxygenase3.320.0044 LRRK2Leucine Rich Repeat Kinase 23.280.0056 IFNBinterferon beta 12.640.0104 TLR10Toll Like Receptor 103.080.0122 TLR3Toll Like Receptor 33.040.0122 IL18Interleukin 182.650.014 OAS12′-5′-oligoadenylate synthetase 12.510.0376 IL15Interleukin 152.420.0446ENL vs No Reaction PARKparkinson protein 2, E3 ubiquitin protein ligase2.130.0436ENL vs RR TLR7Toll Like Receptor 7−2.720.0214^\*^The genes were defined as differentially expressed by the criterion of *p*-value adjusted for multiple comparisons. Bayesian statistical analysis used a log fold change cutoff of \> 1 and adjusted *p* value of \< 0.05. - Abbreviations: *RR* reversal reaction, *ENL* erythema nodosum leprosumFig. 1Gene expression of whole blood leukocytes in patients with RR as compared to patients without leprosy reactions. A group of genes differentially expressed in RR samples was identified, consisting of 1 chemokine gene (*CCL2* logFC = 4.04), 2 PARK genes (*PARK* logFC =3.27, *LRRK2* logFC =3.09), 1 eicosanoid metabolism gene (*ALOX5* logFC =2.99), 4 pattern recognition receptor genes (Toll-like receptors -TLRs: *TLR7* logFC =2.98, *TLR10* logFC =3.07, *TLR3* logFC =2.74, and C-lectin receptors-CLRs: *CLEC5A* logFC =2.81), 2 cytokine genes (*IL18* logFC =2.34, *IL15* logFC = 2.42) and 2 type I IFN genes (*IFNB* logFC =2.36, *OAS1* logFC = 2.51)

Discussion {#Sec3}
==========

Our RR signature corroborates data showing that *M. leprae* components and host cell destruction continue to stimulate the immune response in a sudden and acute manner during RR. Most pathogen-associated molecular patterns (PAMPs) and damage-associated molecular pattern molecules (DAMPs) bind specific PRRs such as Toll-like receptors and NOD-like receptors to orchestrate both, autophagy and IFN signaling \[[@CR12], [@CR13]\]. We hypothesized that the continued binding of PAMPs and DAMPs to TLRs caused by the pathogen components after killing destruction provides the necessary trigger for maintenance of the inflammatory process. The stimulation of innate mechanisms that comprise genes with autophagic activities such as *PARK* and *LRRK2*, in addition to the type I IFNs in the beginning of the process seems to be activated in order to clear killed mycobacteria, but it is unbalanced and exacerbated. Regarding the IFNs, the genes IFNB and *OAS1* (2--5 'oligoadenylate synthetase-1 gene) had a greater expression in RR samples. *OASL* was also shown to be upregulated in *M. leprae*--infected human macrophage cell lineages, primary monocytes, and skin lesion from patients with a disseminated form of leprosy; whereas *OASL* knock down was associated with decreased viability of *M. leprae* and upregulation of autophagy levels \[[@CR14]\]. Additionally, the chemokine *CCL2* was the most expressed gene in our RR group. Recent reports have linked the STING signaling, type I IFN and CCL2 activation \[[@CR14], [@CR15]\]. During mycobacterial infection, this chemokine can be produced in a STING-dependent manner and it is actively involved in the recruitment of monocytes to the infection site \[[@CR15]\] and also related to mycobacterial survival within macrophages \[[@CR14]\]. Other works have pointed the participation of CCL2 in the pathogenesis of several inflammatory disorders such as atherosclerosis and autoimmune diseases \[[@CR16]--[@CR18]\]. Here, we could speculate that a prominent triggering of STING signaling and high expression of type I IFN and CCL2 may contribute to the attraction of immune cells and enhancement of inflammatory response during leprosy reaction.

Type 1 reaction or RR is caused by an amplified immune response possibly triggered by fragmented bacillary antigens available in the cell medium \[[@CR19]\]. The main issue however, is that a dysregulated process of gene activation, aiming to contain the progress of *M. leprae* and eliminate the infection, will lead to the nerve and tissue damage. Indeed, persons with history of RR can keep an altered response to *M. leprae* antigens that differs from patients with unreactional leprosy for years after resolution of RR \[[@CR8]\]. Additionally, our results show that the expression of *TLR3, TLR7* and *TLR10* were significantly increased in the reactions per se as well as in RR with *TLR7* and *TLR10* corroborating with data that fragments of bacterial destruction may be giving continuity to the characteristic inflammatory process of both reactional episodes in leprosy. On the other hand, ENL is characterized by a systemic inflammatory reaction. In this case, it might be possible that other set of genes related to the humoral immune response would be more active in these leucocytes. We need to expand our panel in order to identify which profile explains ENL.

Conclusion {#Sec4}
==========

Overall our data strength previous data and reinforces a signature for RR that could help to guide future studies for developing tools to predict this condition among leprosy patients. Personalizing the treatment of individuals susceptible to the development of reactions will help increase the effectiveness of treatment and reduce morbidity and disability in leprosy.
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